Zanubrutinib (ZB), a second-generation BTK inhibitor, is currently used in the treatment of capsid cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [19]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.